Novartis India Board to Consider Rights Issue on Oct 8, 2026
Novartis India Ltd (now Evonile Pharma Limited) has informed BSE that its Board of Directors will convene a meeting on Thursday, October 08, 2026. The main purpose of the meeting is to consider and approve a proposal to raise funds through a rights issue. This rights issue would involve the issuance of equity shares, each with a face value of ₹5, to eligible equity shareholders. The fund-raising initiative is contingent upon receiving all necessary regulatory, statutory, and other applicable approvals. The company also reiterated that the trading window for designated persons is already closed from October 01, 2026, until November 05, 2026, due to the upcoming unaudited financial results for the quarter and nine months ended September 30, 2026.
Key Highlights
- Board meeting scheduled for October 08, 2026.
- Board to consider fund-raising via a rights issue.
- Rights issue involves equity shares with ₹5 face value.
- Fund-raising is subject to all necessary approvals.
- Trading window already closed for Q3 2026 results.
Price Impact
More from NOVARTIND